Publications by authors named "Rosa Fernandez Olmo"
ApoB and prognosis of patients with chronic coronary syndrome.
Rev Esp Cardiol (Engl Ed)
October 2024
Background: Decision tree algorithms, obtained by machine learning, provide clusters of patients with similar clinical patterns by the identification of variables that best merge with a given dependent variable.
Methods: We performed a multicenter registry, with 7 hospitals form Spain, of patients with, or high-risk of having, coronary heart disease (CHD). Elevated Lp(a) was defined as >50 mg/dl.
Objectives: To gather opinions, recommendations, and proposals for improvement from Spanish clinicians on cardiovascular (CV) health, with particular focus on dyslipidemia management.
Methods: The Expert Insights project involved 8face-to-face sessions held throughout Spain, attended by 138 CV health experts. Clinicians answered to 25 questions survey related to CV health and dyslipidemia control.
Article Synopsis
- Lipoprotein(a) [Lp(a)] is a particle linked to higher cardiovascular risk and is largely influenced by genetics, prompting this study to investigate Lp(a) levels in relatives of patients with acute coronary syndrome (ACS).
- A multicenter study included 413 subjects, where 56.4% were first-degree relatives of patients with Lp(a) levels ≥ 50 mg/dL; notably, 57.5% had a family history of early ischemic heart disease, and only 20.6% were on statin treatment.
- Findings showed that 59.4% of these relatives had elevated Lp(a) levels, which were comparable to the patients, indicating a familial predisposition to high L
Cardiovascular considerations on recreational scuba diving. SEC-Clinical Cardiology Association/SEC-Working Group on Sports Cardiology consensus document.
Rev Esp Cardiol (Engl Ed)
July 2024
The practice of recreational scuba diving has increased worldwide, with millions of people taking part each year. The aquatic environment is a hostile setting that requires human physiology to adapt by undergoing a series of changes that stress the body. Therefore, physical fitness and control of cardiovascular risk factors are essential for practicing this sport.
View Article and Find Full Text PDFLipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer, especially for predicting the risk of long-term recurrent AMI. We aimed to assess the relation between Lp(a) and very long-term recurrent AMI after an index episode of AMI.
View Article and Find Full Text PDFBackground: Statins are the cornerstone of lipid-lowering therapy (LLT) for reduction of low-density lipoprotein cholesterol (LDLc) levels and high percentage of patients require LLT combinations or alternative treatments for adequate LDLc control.
Methods: We performed an intention-to-treat meta-analysis of published data of phase III trials evaluating LLT efficacy on major adverse cardiovascular events (MACE). The primary endpoint was MACE incidence, as reported in each trial, and secondary analyses included myocardial infarction, stroke and mortality.
Bempedoic acid is a selective inhibitor of the adenosine triphosphate citrate lyase that reduces low-density lipoprotein cholesterol (LDLc) levels by 17% to 28%. Although the Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (CLEAR-OUTCOMES) trials demonstrated the efficacy on cardiovascular outcomes there is a controversy related to the possible net clinical benefit. Thereafter, we performed an intention-to-treat meta-analysis in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
View Article and Find Full Text PDFBackground: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies targeting PCSK9 significantly lower LDL cholesterol levels by about 55% in patients, but their impact on other lipid parameters like cholesterol remnants is less clear.
- A study analyzing data from 652 patients across 14 hospitals in Spain showed that treatment with PCSK9 inhibitors not only reduced LDL cholesterol but also led to significant decreases in other lipid measures, including the triglycerides-to-HDL ratio and cholesterol remnants.
- The findings indicate that over one-third of patients achieved LDL cholesterol below 55 mg/dl and lower cholesterol remnants, suggesting that PCSK9 inhibitors are effective in managing lipid residual risk as well as LDL cholesterol levels.
Article Synopsis
- Life expectancy has risen significantly, highlighting the need for targeted health interventions to improve outcomes for elderly patients with cardiovascular issues.
- Current clinical guidelines lack specific recommendations for older adults due to their low representation in clinical trials.
- This document focuses on preventative care for patients aged 75 and older, addressing treatment options, physical exercise, and the importance of considering geriatric syndromes and comorbidities in their management.
Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF). This meta-analysis aims to assess the effect of DOACS vs. VKA in patients ≥ 80 and AF.
View Article and Find Full Text PDFPurpose: Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors treatment induce large reductions in low-density lipoprotein cholesterol (LDLc) and major cardiovascular events. Clinical trials might have been underpowered to test the effect of PSCK9 inhibitors treatment on myocardial infarction and stroke, two of the most relevant cardiovascular events, since all analyzed a combined endpoint.
Methods: we performed a meta-analysis, with currently available studies involving PCSK9 inhibitors and event rate adjudication, with the aim of assessing treatment effects on myocardial infarction and stroke.
Comments on the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases.
Rev Esp Cardiol (Engl Ed)
February 2018